| 1 |
33353450 | 5-Aza-2'-deoxycytidine may enhance the frequency of T regulatory cells from CD4+ naïve T cells isolated from the peripheral blood of patients with chronic HBV infection. | 2021 Feb |
1 |
| 2 |
34295326 | Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer. | 2021 |
1 |
| 3 |
34368325 | Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report. | 2021 Jul 26 |
2 |
| 4 |
33194624 | Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer. | 2020 |
3 |
| 5 |
29622799 | Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. | 2019 Apr |
1 |
| 6 |
27686004 | Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome. | 2017 Apr |
2 |
| 7 |
27808592 | PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS. | 2017 Apr |
1 |